Staffan Gustavsson

Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden

L. Levin, A. Wiréhn, U. Rosenqvist, 2020, Diabetes Therapy.

Disease Burden and Healthcare Costs for T2D Patients With and Without Established Cardiovascular Disease in Sweden: A Retrospective Cohort Study

L. Levin, A. Wiréhn, U. Rosenqvist, 2020, Diabetes Therapy.

Burden of established cardiovascular disease in people with type 2 diabetes and matched controls: Hospital‐based care, days absent from work, costs and mortality

J. Skogsberg, S. Persson, J. Jendle, 2022, Diabetes, obesity & metabolism.

Model‐based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease

J. Skogsberg, S. Persson, E. Andersson, 2022, Diabetes, obesity & metabolism.